CTLA4 and gastric cancer: A recent case report showed hyperprogression of the lymph nodes and liver lesions compressing the gastric stump from a 68-year-old patient with stage IV MSI subtype GC after receiving immunotherapy of durvalumab (PD-1 inhibitor) and tremelimumab (CTLA-4 inhibitor).421 More study is still needed to evaluate the therapeutic significance of CTLA-4 in GC.